SNUG01 Clinical Study Officially Launched in the Third Hospital of Beijing Medical University
On September 22, 2023, a clinical research (IIT) project of SNUG01, a gene therapy drug for amyotrophic lateral sclerosis (ALS, also known as ALS), was successfully launched in the Third Hospital of Peking University (the Third Hospital of Beijing Medical University). Professor Fan Dongsheng's team from the Third Hospital of Beijing Medical University, Jia Yichang's laboratory team from Tsinghua University, founder of Shenji Changhua and clinical team attended the kick-off meeting.
![](http://nwzimg.wezhan.cn/contents/sitefiles2063/10317530/images/46108582.png)
kick-off meeting site
project is "a single-arm, open exploratory clinical study to evaluate SNUG01 single intrathecal injection in patients with amyotrophic lateral sclerosis". It is an IIT study sponsored by Professor Fan Dongsheng, a famous expert on ALS, as the main researcher and funded by Shenji Changhua. SNUG01 is a gene therapy drug with adeno-associated virus (AAV) as the carrier and the exclusive therapeutic target SG001 of Shenji Changhua, in order to achieve the therapeutic effect of "one-time administration, long-term effective.This project will rely onone of the largest treatment and research centers of progressive freezing disease in ChinaDepartment of Neurology, the Third Hospital of North Medical College, make full use of itson clinical resources.
![](http://nwzimg.wezhan.cn/contents/sitefiles2063/10317530/images/46108583.png)
Professor Fan Dongsheng
Professor Fan Dongsheng said at the kick-off meeting that there are few basic research clinical translational medicine projects for ALS in China. SNUG01 clinical research has solid preclinical data, and the first sympathetic drug administration has preliminarily verified its safety and efficacy. Its therapeutic target SG001 has significant neuron protection and has great clinical therapeutic potential. He is full of expectations for the SNUG01 clinical research launched in the Third Hospital of Beijing Medical University. He believes that the launch of SNUG01 clinical research will be a milestone event. The Third Hospital of Beijing Medical University will join hands with Shenji Changhua to actively promote this clinical research.
![](http://nwzimg.wezhan.cn/contents/sitefiles2063/10317530/images/46108586.png)
Professor Jia Yichang
Shenji Changhua Science and professor of medicine at Tsinghua University, said that SNUG01 uses a new therapeutic target for ALS, which has been rigorously scientifically verified. The successful start of this IIT clinical study is inseparable from the hard work of the front-line researchers in Jia Yichang Laboratory of Tsinghua University, the cooperation of Shenji Changhua clinical and non-clinical teams, and the strong support of Professor Fan Dongsheng's team from the Third Hospital of Beijing Medical University.
![](http://nwzimg.wezhan.cn/contents/sitefiles2063/10317530/images/46108584.png)
scene photo
This launch marks the first gene therapy drug of Shenji Changhua into a new stage of clinical research, the next step Shenji Changhua will continue to promote clinical research work with a scientific and pragmatic attitude, to help the research center clinical research high-quality development. The clinical application of SNUG01 is expected to open a new field of ALS treatment, bring new hope for patients and their families, and is of great significance to explore new treatment methods for ALS.
patient recruitment
dear patient friend: